Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track QUCY with free AI briefings, catalyst countdowns, and dilution alerts.

QUCY · Quantum Cyber N.V.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1M Cash on Hand

0.6mo Cash Runway

Follow QUCY by email Get an email when QUCY pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about QUCY, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Apr 2026 · N/A · Results Expected · Evaluation of the Efficacy and Safety of Dallixa® Eyebrow Serum (Produced by Quantum Aesth
Registry primary completion date, not a results date
Feb 2026 · Phase 4 · Results Expected · Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash Hypotrichosis
Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device
Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device
Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device
Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
dermo cosmetic product	Hypotrichosis	Phase 4 · NCT07776028	Completed
Firibastat	Hypertension	Phase 3 · NCT04277884	Completed
Firibastat (QGC001) Period 1	Hypertension (HTN)	Phase 3 · NCT04857840	Terminated
Dendritic Cell Vaccination	Breast Cancer	Phase 1/2 · NCT00879489	Unknown
Ultra-micronized Palmitoyl Ethylamine (P	Mast Cell Activation Syndrome	Phase 2 · NCT05652907	Terminated
QGC001	Hypertension	Phase 2 · NCT03198793	Completed
Lucid-21-302	Healthy Participants	Phase 1 · NCT05821387	Completed
QGC001 [(3S,3'S)-4,4'-dithiobis (3-amino	Essential Hypertension	Phase 1 · NCT01900171	Completed

Also used in these trials (approved or third-party drugs, not QUCY's own candidates): Ramipril.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

QUCY holds $1M in cash and short-term investments (as of Aug 12, 2026) and burns about $4.9M/quarter from operations, an estimated runway of 0.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Cash runway 1 months +40
Going-concern doubt in the latest 10-Q +15These conditions raise substantial doubt about the Company’s ability to continue as a going concern. 10-Q, Aug 2026

Recent financing filings on SEC EDGAR:

Apr 28, 2026 · Private placement (8-K Item 3.02) · 8-K
Feb 17, 2026 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when QUCY files for a raise →

Get the full QUCY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QUCY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z